Your browser is no longer supported. Please, upgrade your browser.
Settings
ABBV AbbVie Inc. daily Stock Chart
ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E17.99 EPS (ttm)3.65 Insider Own0.10% Shs Outstand1.59B Perf Week-0.38%
Market Cap104.64B Forward P/E10.13 EPS next Y6.48 Insider Trans-8.69% Shs Float1.59B Perf Month6.99%
Income5.95B PEG1.23 EPS next Q1.26 Inst Own69.40% Short Float1.88% Perf Quarter6.68%
Sales25.64B P/S4.08 EPS this Y16.20% Inst Trans-2.00% Short Ratio4.32 Perf Half Y4.41%
Book/sh2.87 P/B22.87 EPS next Y17.89% ROA9.40% Target Price70.11 Perf Year20.94%
Cash/sh4.03 P/C16.29 EPS next 5Y14.61% ROE111.30% 52W Range53.19 - 66.82 Perf YTD5.90%
Dividend2.56 P/FCF36.78 EPS past 5Y10.90% ROI18.00% 52W High-1.77% Beta1.55
Dividend %3.90% Quick Ratio1.50 Sales past 5Y8.00% Gross Margin77.30% 52W Low23.41% ATR0.84
Employees30000 Current Ratio1.70 Sales Q/Q6.20% Oper. Margin36.60% RSI (14)65.81 Volatility1.02% 1.30%
OptionableYes Debt/Eq7.95 EPS Q/Q-7.30% Profit Margin23.20% Rel Volume0.45 Prev Close65.65
ShortableYes LT Debt/Eq7.86 EarningsApr 28 BMO Payout62.10% Avg Volume6.93M Price65.64
Recom2.50 SMA201.82% SMA505.11% SMA2006.18% Volume2,968,991 Change-0.02%
Mar-22-17Upgrade Societe Generale Sell → Hold
Oct-31-16Downgrade Credit Suisse Outperform → Neutral
Oct-18-16Initiated Leerink Partners Mkt Perform $70
Sep-08-16Downgrade JP Morgan Overweight → Neutral
Sep-02-16Initiated Raymond James Outperform $82
Jun-08-16Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-06-16Initiated Societe Generale Sell $47
Mar-15-16Initiated Deutsche Bank Hold $63
Feb-23-16Upgrade Citigroup Neutral → Buy
Dec-01-15Downgrade Barclays Overweight → Equal Weight $73 → $72
Nov-02-15Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-23-15Reiterated UBS Buy $81 → $78
Sep-28-15Upgrade Citigroup Sell → Neutral
Jul-22-15Initiated Sun Trust Rbsn Humphrey Buy
Jun-17-15Initiated Piper Jaffray Overweight
Jun-08-15Reiterated Jefferies Buy $86 → $90
May-28-15Resumed Morgan Stanley Equal-Weight $72
May-27-15Resumed JP Morgan Overweight $75
Jan-06-15Reiterated UBS Buy $72 → $76
Nov-26-14Reiterated Argus Buy $65 → $85
Mar-24-17 11:27AM  Amgen's (AMGN) Humira Biosimilar Receives Approval in EU
08:27AM  Bernie Sanders thinks this $89,000-a-year drug should be $1,000 a year at MarketWatch
Mar-23-17 07:45AM  Julianne Hough Empowers Women to "Get in the Know" About Endometriosis PR Newswire
12:51AM  [$$] Rare Discovery: A Value in the Biotech World at The Wall Street Journal
Mar-22-17 05:22PM  Galapagos Begins Cystis Fibrosis Treatment Study
01:39PM  AbbVie upgraded by Societe Generale
01:12PM  [$$] Rare Discovery: A Value in the Biotech World at The Wall Street Journal
08:15AM  Blog Coverage Eli Lilly Announced Positive Results from Breast Cancer Drug Combination Study Accesswire
Mar-21-17 07:51AM  Novartis Cosentyx Shows Psoriasis Modification Potential (NVS, DERM) at Investopedia
07:00AM  Our Ultimate Stock-Pickers' Top 10 Dividend-Yielding Stocks at Morningstar
Mar-20-17 07:18PM  [$$] New Enterprise Associates Joins SetPoint Medical Syndicate at The Wall Street Journal
11:55AM  Forbes: Eight of the worlds billionaires call Tampa Bay home at bizjournals.com
09:35AM  Update in Lawsuit for Investors in NYSE: ABBV Shares Against AbbVie Inc. Announced by Shareholders Foundation Accesswire
Mar-16-17 10:49AM  Pfizer's Arthritis Drug Xeljanz Gets Marketing Nod in China
08:46AM  Biotech Stock Roundup: Amgen's Data on Repatha, Catalyst Soars on Firdapse Data
Mar-15-17 05:43PM  AbbVie's Hepatitis C Treatment Under Priority Review in Japan
09:24AM  3 Stocks to Add to Your Social Security Income at Motley Fool
Mar-14-17 04:46PM  AbbVie Receives An Upgrade From Vetr
08:00AM  AbbVie Granted Priority Review in Japan for its Investigational Regimen of Glecaprevir/Pibrentasvir (G/P) for the Treatment of All Major Genotypes of Chronic Hepatitis C PR Newswire
07:02AM  3 High-Yield Investments in Healthcare at Motley Fool
Mar-13-17 06:50PM  Cramer's Lightning Round: The price to strike with Exxon this week at CNBC
05:16PM  Goldman Sachs Adds AbbVie to Conviction List
08:41AM  The 19 Best-Selling Prescription Drugs of All-Time at Motley Fool
Mar-11-17 11:41AM  Which Biotech Is the Best Dividend Stock? at Motley Fool
Mar-10-17 04:40PM  AbbVie Outperforms Drug Stocks On $20.5 Billion Growth View
04:31PM  US STOCKS-Wall St ends up; jobs data points to economic strength
04:02PM  AbbVie Price Target Hiked, Marathon Oil Rated Outperform
01:12PM  AbbVie Stock Upgraded: What You Need to Know at Motley Fool
01:03PM  US STOCKS-Wall St trims gains as jobs data paves Fed path to hike rates Reuters
12:45PM  These 2 Dividend Aristocrats Are Ridiculously Cheap at Motley Fool
12:20PM  AbbVie: Be More Like Google? at Barrons.com
11:26AM  US STOCKS-Wall St rises as robust jobs report lifts mood Reuters
10:21AM  AbbVie, Inc. :ABBV-US: Earnings Analysis: Q4, 2016 By the Numbers : March 10, 2017
08:45AM  Top Analyst Upgrades and Downgrades: AbbVie, KLA-Tencor, Marathon Oil, Verifone and Many More
Mar-09-17 04:55PM  Will Merck, Glaxo Undercut Gilead's Next 'Mount Everest' Drug?
09:21AM  AbbVie at the Cowen Healthcare Conference: 4 Things You'll Want to Know at Motley Fool
06:04AM  Germany's Merck well advanced in talks to sell biosimilars unit
Mar-08-17 05:15PM  AbbVie Is a Screaming Dividend Growth Buy... Here's Why
03:38PM  Billionaire Investor Is Concentrating on Small-Caps and Pharma
12:29PM  Results of Johnson & Johnson's Psoriasis Clinical Trials Impressive
Mar-07-17 04:21PM  Novartis (NVS) Reports Positive Data on Biosimilar Humira
10:05AM  Jefferies Strongly Reiterates Top Pick Call On AbbVie
10:05AM  AAA Credit Rating Stocks in Focus: Johnson & Johnson
Mar-06-17 03:53PM  TG Therapeutics Surges 85% on Results From Study
01:15PM  Why TG Therapeutics Stock Exploded Higher Today at Motley Fool
10:35AM  TG Therapeutics' leukemia drug clears key study, shares pop
10:32AM  In A Blow To AbbVie Inc (ABBV) Humira, Market For Biosimilars Opened Wide at Insider Monkey
09:28AM  Inovio (INO): What's in the Cards this Earnings Season?
08:41AM  J&J Presents Positive Phase III Data on Psoriasis Candidate
07:14AM  TG Therapeutics' leukemia drug clears hurdle in key study
Mar-05-17 11:06PM  UK court delivers high-stakes decision on world's best-selling drug at CNBC
08:21AM  5 Dividend Stocks to Buy in March at Motley Fool
Mar-03-17 02:25PM  AbbVie, Inc. : ABBV-US: Dividend Analysis : January 13th, 2017 (record date) : By the numbers : March 3, 2017
Mar-02-17 12:12PM  These 3 Big Pharma Stocks Are Exceptionally Cheap at Motley Fool
11:18AM  AbbVie, a 2017 Dividend Pick, Could Turn to the Upside
Mar-01-17 04:41PM  Better Buy: Johnson & Johnson vs. AbbVie at Motley Fool
10:37AM  How Gileads Liver Disease Drugs Portfolio Performed
08:00AM  AbbVie to Present at the Barclays Global Healthcare Conference PR Newswire
Feb-28-17 03:42PM  Get Paid While You Wait: 3 Top Dividend Stocks in Big Pharma at Motley Fool
02:15PM  AbbVie Regimen Recommended for HCV Infection
10:46AM  Aytu BioScience May Lead the Way in Low T
Feb-27-17 04:46PM  Pfizer Reports Top-Line Results for Rheumatoid Arthritis Treatment Study
04:00AM  AbbVie Receives CHMP Positive Opinion for Eight-Week Treatment Option with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) + EXVIERA® (dasabuvir tablets) for Patients with Genotype 1b Chronic Hepatitis C PR Newswire
01:51AM  Facing Criticism, Drug Makers Keep Lid On Price Increases at The Wall Street Journal
Feb-26-17 08:03PM  Drug Companies Keep Lid on Price Increases at The Wall Street Journal
Feb-24-17 04:14PM  Gilead, AbbVie Could Perk Up On Merck's Hep C Downfall: Leerink
10:57AM  3 Incredibly Cheap Biotech Stocks at Motley Fool
Feb-23-17 05:08PM  2 Dividend Aristocrats Trading At A Discount
05:06PM  AbbVie Stronger Bet Than Gilead, Amgen At Least Until 2020: Leerink
01:04PM  ABBVIE INC. Financials
12:55PM  Questions Linger About AbbVie's AndroGel at Investopedia
10:48AM  These 3 Dividend Stocks Are Ridiculously Cheap at Motley Fool
Feb-21-17 03:11PM  AbbVie Declares Quarterly Dividend
11:11AM  AbbVie Inc (ABBV) In Share Buyback Plan For The Third Year In A Row at Insider Monkey
07:15AM  AbbVie, Inc. breached its 50 day moving average in a Bullish Manner : ABBV-US : February 21, 2017
Feb-17-17 12:22PM  ABBVIE INC. Files SEC form 10-K, Annual Report
09:07AM  Parsabiv Is Expected to Boost Amgens Revenues in 2017
08:13AM  Pfizer's Xeljanz Combo Comparable to AbbVie's Humira
08:00AM  AbbVie Announces $5 Billion Increase to Stock Repurchase Program PR Newswire
Feb-16-17 01:35PM  NICE Rejects AbbVies Leukemia Drug Venclexta at Investopedia
01:15PM  UK National Institute For Health And Care Excellence Rejects Leukemia Drug From AbbVie Inc (ABBV) at Insider Monkey
12:41PM  AbbVie Declares Quarterly Dividend PR Newswire
09:42AM  Why I Just Bought AbbVie Stock at Motley Fool
08:16AM  Pfizer says rheumatoid arthritis drug is comparable to Humira as combination treatment but not alone at MarketWatch
Feb-15-17 10:42AM  Eli Lilly Is Great Stock to Buy Now
08:10AM  No Joke: Johnson & Johnson Could Grow Sales by 5% (or More) Annually Over the Next Decade at Motley Fool
08:01AM  AbbVie to Present at the Cowen and Company 37th Annual Health Care Conference PR Newswire
Feb-14-17 10:28AM  3 Top Biotech Stocks to Buy on Sale at Motley Fool
02:00AM  These drug and medical device companies made the most payments to N.Y.C. hospitals at bizjournals.com
Feb-11-17 09:05AM  Better Buy: AbbVie Inc. vs. Eli Lilly at Motley Fool
Feb-10-17 04:20PM  Here's Why M&A Has Tesaro's Stock Soaring 40% In 2017 at Motley Fool
03:42PM  3 Trump-Proof Dividend Stocks to Buy Right Now at Motley Fool
08:35AM  Are Short Sellers Doubting Trump by Hiking Bets in Major Pharma?
Feb-09-17 01:35PM  Why OraSure Technologies, Inc. Leaped Higher Today at Motley Fool
08:50AM  10 Best Dividend-Paying Stocks for 2017 at Kiplinger
Feb-08-17 03:33PM  Finding the Best Value Investment in Healthcare at Investopedia
11:39AM  Gilead Hepatitis C Meltdown Raises Troubling Question: Is Curing Disease Bad for Business?
09:30AM  The Zacks Analyst Blog Highlights: Apple, Visa and AbbVie
Feb-07-17 06:58PM  Gilead 2017 hepatitis C sales forecast disappoints, shares drop
05:22PM  Streamlined FDA Approval Process Would Boost Drug Makers
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus(HIV)-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a subcutaneous treatment for relapsing forms of multiple sclerosis. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has collaboration agreements with C2N Diagnostics; Calico Life Sciences LLC; and Infinity Pharmaceuticals, Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Schumacher Laura JExecutive Vice PresidentMar 10Sale65.2640,0002,610,257107,825Mar 10 05:22 PM
Michael Robert A.VP, ControllerMar 10Sale65.295,132335,06816,706Mar 10 05:22 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesMar 10Sale65.2922,4511,465,82626,078Mar 10 05:21 PM
GONZALEZ RICHARD AChairman of the Board and CEOMar 08Option Exercise27.9572,0162,012,610422,763Mar 10 05:20 PM
GONZALEZ RICHARD AChairman of the Board and CEOMar 08Sale64.2572,0164,627,028350,747Mar 10 05:20 PM
HURWICH THOMAS A.VP, ControllerFeb 28Sale61.892,311143,03167,276Mar 02 06:12 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 02Option Exercise27.292,40065,4965,431Feb 03 05:21 PM
CHASE WILLIAM JEVP, Chief Financial OfficerDec 02Option Exercise27.296,600180,114178,970Dec 02 05:08 PM
CHASE WILLIAM JEVP, Chief Financial OfficerDec 02Sale59.196,600390,654172,370Dec 02 05:08 PM
HURWICH THOMAS A.VP, ControllerNov 16Option Exercise28.863,10089,47564,549Nov 18 05:39 PM
HURWICH THOMAS A.VP, ControllerNov 16Sale62.003,100192,20061,449Nov 18 05:39 PM
Schumacher Laura JExecutive Vice PresidentSep 07Sale65.0050,0003,250,000144,138Sep 09 05:38 PM
Schumacher Laura JExecutive Vice PresidentJun 24Option Exercise27.62186,1065,140,971380,244Jun 28 05:47 PM
Schumacher Laura JExecutive Vice PresidentJun 24Sale60.03186,10611,171,173194,138Jun 28 05:47 PM
GONZALEZ RICHARD AChairman of the Board and CEOJun 02Sale63.82285,95318,249,712338,421Jun 03 05:26 PM
GONZALEZ RICHARD AChairman of the Board and CEOMay 11Sale63.8039,0002,488,200338,421May 13 05:11 PM
HURWICH THOMAS A.VP, ControllerMay 10Option Exercise27.296,000163,74068,204May 12 05:44 PM
ALBAN CARLOSEVP, Commercial OperationsMay 10Sale63.5247,4383,013,262149,444May 12 05:39 PM
HURWICH THOMAS A.VP, ControllerMay 10Sale63.596,000381,54162,204May 12 05:44 PM